Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case 
China Eastern Orders 25 Airbus A330neo Jets in $9.35 Billion Deal to Boost International Expansion 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
SpaceX, Charter Communications Explore Mobile Partnership to Expand Starlink Wireless Service 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
BRIDGEWATER, N.J., May 08, 2017 -- Valeritas Holdings, Inc. (NASDAQ:VLRX) announced today that the Company is scheduled to present at the 18th Annual B. Riley Co. Investor Conference.
| Event: | 18th Annual B. Riley Co. Investor Conference |
| Format: | Presentation and One-on-One Meetings |
| Date: | Wednesday, May 24, 2017 |
| Time: | 1:00pm PT |
| Location: | Santa Monica, CA |
An audio webcast of the Company’s presentation will be available by visiting the investor relations section of the Valeritas website at www.valeritas.com. Replays of the presentation will be available for 90 days.
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.
Investor Contacts: Nick Laudico / Robert Flamm, Ph.D. The Ruth Group 646-536-7030 / 7017 [email protected] Or The Del Mar Consulting Group, Inc. Robert B. Prag, President 858-794-9500 [email protected] Media Contact: Kirsten Thomas The Ruth Group 508-280-6592 [email protected]
